ARGSQ - Argos Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5688.13k
Enterprise Value 311.23M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)0.08
Price/Book (mrq)N/A
Enterprise Value/Revenue 31.26
Enterprise Value/EBITDA 6-0.67

Trading Information

Stock Price History

Beta (3Y Monthly) 3.45
52-Week Change 3-58.60%
S&P500 52-Week Change 35.84%
52 Week High 30.2500
52 Week Low 30.0190
50-Day Moving Average 30.0651
200-Day Moving Average 30.0729

Share Statistics

Avg Vol (3 month) 313.27k
Avg Vol (10 day) 33.03k
Shares Outstanding 54.43M
Float 9.2M
% Held by Insiders 111.27%
% Held by Institutions 11.10%
Shares Short (Mar 29, 2018) 4648.84k
Short Ratio (Mar 29, 2018) 40.94
Short % of Float (Mar 29, 2018) 49.57%
Short % of Shares Outstanding (Mar 29, 2018) 48.20%
Shares Short (prior month Feb 28, 2018) 4504.41k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 220/1
Last Split Date 3Jan 19, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2017
Most Recent Quarter (mrq)Sep 30, 2018


Profit Margin -173.87%
Operating Margin (ttm)-209.21%

Management Effectiveness

Return on Assets (ttm)-63.60%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)8.91M
Revenue Per Share (ttm)1.05
Quarterly Revenue Growth (yoy)2,231.40%
Gross Profit (ttm)1.9M
EBITDA -16.74M
Net Income Avi to Common (ttm)-15.48M
Diluted EPS (ttm)-1.8300
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)7.94M
Total Cash Per Share (mrq)0.75
Total Debt (mrq)18.49M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.96
Book Value Per Share (mrq)-1.19

Cash Flow Statement

Operating Cash Flow (ttm)-18.56M
Levered Free Cash Flow (ttm)423.04k